A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

Egyesitett Szt.István és Szt. László Kórház, Budapest

Synexus Gyula AS, Gyula

Mentaház Magánorvosi Központ Kft., Székesfehérvár

McILwain Medical Group, Tampa

WALLACE, Los Angeles

East Bay Rheumatology Medical, San Leandro

Denver Arthritis Clinic, Denver

Arthritis and Rheumatic Disease Specialties, Aventura

Arthritis Research & Treatment Center, Stockbridge

Innovative Health Research, Las Vegas

Thurston Arthritis Research Center, Chapel Hill

DJL Clinical Research, PLLC, Charlotte

Revmatologie s.r.o., Brno

CHU Felix Guyon, Saint-Denis

Hopital Haut Lévêque, Bordeaux

Hôpital européen, Marseille

GHR Mulhouse Sud-Alsace, Mulhouse

Hôpital Cochin, Paris

CHU Strasbourg Hôpital de Hautepierre, Strasbourg

CHU Strasbourg Nouvel Hôpital Civil, Strasbourg

Schlosspark-Klinik Berlin, Berlin

Clinic for Rheumatology and Internal Medicine, Freiburg im Breisgau

University of Debrecen Medical Center Department of Clinical Immunology, Debrecen

Cap Research, Phoenix

Centrum Medyczne Plejady, Krakow

Krakowskie Centrum Medyczne, Krakow

Centrum Medyczne Hetmańska, Poznan

Centrum Medyczne Oporow, Wroclaw

Revmatologický ústav v Praze, Prague

Latin Clinical Trial Center, San Juan